-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK's Efimosfermin Receives FDA's Breakthrough Therapy Designation, European Medicines Agency's Priority Medicines Designation To Treat Metabolic Dysfunction-Associated Steatohepatitis

Benzinga·04/27/2026 16:25:56
Listen to the news